WuXi Biologics Reports Solid 2023 Annual Results
- Written by PR Newswire
Revenue Increased by 11.6% Y-o-Y to RMB17,034.3 Million
Gross Profit Rose by 1.5% to RMB6,827.9 Million
Non-COVID Revenue Achieved 37.7% Y-o-Y Growth, Strong Momentum Sustained
Non-COVID Late-Phase and Commercial Manufacturing Revenue Grew by 101.7% Y-o-Y
"R" in CRDMO Thrived with Extended Partnerships, Milestone and Research Services Revenue Exceeded...














